Karin Eastham
CIK 1231845 · last filed 2026-10-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VCYT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VCYT | Director | 14,447 | $24.16 | $349.0K | -$151.04M | 32 | 2026-10-28 |
| PSNL | Director | 19,756 | $15.79 | $311.9K | $0 | 9 | 2026-06-11 |
| GERN | Director | 109,047 | $0.99 | $107.9K | $0 | 22 | 2023-01-17 |
| NKTR | Director | 1,549 | $37.26 | $57.7K | -$76.8K | 7 | 2022-09-20 |
| ILMN | Director | 10,049 | $213.13 | $2.14M | -$18.46M | 34 | 2019-05-28 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | 18,114 | — | — | $0 | 6 | 2013-05-23 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | Director | 6,000 | — | — | $0 | 19 | 2012-05-17 |
| GENOPTIX INC (GXDX) Delisted | Director | 0 | — | — | $0 | 10 | 2011-03-07 |
| SGX PHARMACEUTICALS, INC. (SGXP) Delisted | Director | 0 | — | — | $0 | 4 | 2008-08-21 |
| TERCICA INC (TRCA) Delisted | Director | 13,333 | $7.87 | $104.9K | $0 | 2 | 2008-05-21 |
Recent Filings · Page 10 of 16
159 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-11-04 | VCYT | Conv (C) | +13,227 | $0 | EDGAR |
| 2013-09-13 | — | Disp (D) | −18,114 | $0 | |
| 2013-07-10 | GERN | Disp (D) | −45,000 | $0 | EDGAR |
| 2013-06-05 | ILMN | Mixed | — | -$570.4K | EDGAR |
| 2013-05-31 | ILMN | Grant (A) | +2,500 | $0 | EDGAR |
| 2013-05-24 | GERN | Grant (A) | — | $0 | EDGAR |
| 2013-05-23 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-04-22 | ILMN | Tax (F) | −576 | -$32.4K | EDGAR |
| 2013-01-03 | GERN | Disp (D) | −2,500 | $0 | EDGAR |
| 2012-08-10 | — | Mixed | −6,000 | -$186.0K |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.